Pharmigene EBITDA par action

Que fait Pharmigene ? Pharmigene, Inc. generates revenue through the manufacturing and sale of pharmaceutical genetic diagnostic products, including AutoEx16 automatic nucleic acid extractors, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kits, and SGE 1502, SGE 3101, SGE 5701, Sega 5801, SGE B27, and SGE whole blood calculation and extraction kits. The company offers molecular diagnostic products and testing services such as drug genetic testing, functional medical testing, and personalized genetic testing. Its primary market is Taiwan, with additional presence in other markets. The firm focuses on genomics science for precision medicine, targeting research and development in drug genomics. Pharmigene's product portfolio includes specialized kits for drug genetic testing, such as the Clopidogrel test kit, which assesses genetic variations affecting drug efficacy. The SGE test suites and kits are designed for various diagnostic applications, including whole blood processing and genetic analysis. The company distributes these products through its established market channels in Taiwan and other regions, emphasizing professional solutions for precision medicine. The firm's testing services cater to healthcare providers and research institutions seeking tailored genetic insights. The company's revenue streams are derived from the direct sale of diagnostic kits, testing services, and overall solutions for drug genomics research. Its target segments include healthcare providers, research institutions, and precision medicine developers in Taiwan and other markets. Pharmigene's focus on genetic diagnostic technologies positions it within the niche of pharmaceutical genomics, serving clients who require advanced molecular diagnostics for personalized healthcare approaches. Pharmigene est l'une des entreprises les plus populaires sur Eulerpool.